Search
for
Sort by
Research 30 of 136
- 7410 Bevacizumab Induced Hypothyroidism
- Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study
- Drug Repurposing in Dermatology: Molecular Biology and Omics Approach
- A Melanoma Transplanted in Nude Mice Has Both Host‐ and Tumor‐Derived Blood Vessel‐ and Nerve‐Like Structures
- This Week in JAMA
- Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer
- The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
- Current Therapeutic Approaches to Chronic Central Serous Chorioretinopathy
- Cases update: international roundup of recently filed cases and noteworthy rulings
- Farmácia da Boa Hora, Porto e nos Serviços Farmacêuticos do Hospital Lusíadas, Porto
- Therapeutic Efficacy of Spironolactone for Central Serous Chorioretinopathy
- Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer
- Management of Toxicities of Targeted Therapies
- Woolly Antics between the Sheaths
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Microneedles as the technique of drug delivery enhancement in diverse organs and tissues
- Costunolide—A Bioactive Sesquiterpene Lactone with Diverse Therapeutic Potential
- Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients
- Drug-induced acne
- Recent studies on the delivery of hydrophilic drugs in nanoparticulate systems
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
- Alopecia in patients treated with molecularly targeted anticancer therapies
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Friends Turned Foes: Angiogenic Growth Factors beyond Angiogenesis
- Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Candidate SNP markers of reproductive potential are predicted by a significant change in the affinity of TATA-binding protein for human gene promoters
- Applications and Implications of Heparin and Protamine in Tissue Engineering and Regenerative Medicine
- Oral medications for central serous chorioretinopathy: a literature review